An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS‐CoV‐2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS‐CoV‐2 in vitro. © 2020 Wiley Periodicals LLC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 25, 2020
- Source ID
- 10.1002/cpmc.108
Entities
People
- Adolfo García‐sastre
- Fatima Amanat
- Florian Krammer
- Kris M White
- Lisa Miorin
- Luis Martinez‐sobrido
- Meagan Mcmahon
- Philip Meade
- Randy A. Albrecht
- Shirin Strohmeier
- Thomas Moran
- Viviana Simon
- Wen‐chun Liu
Organizations
- Defense Advanced Research Projects Agency
- Icahn School of Medicine at Mount Sinai
- National Institute of Allergy and Infectious Diseases
- Texas Biomedical Research Institute